Clinical Report: CAR-T therapy utilizing Oncostatin-M ligand demonstrates significant anti-tumor efficacy in osteosarcoma treatment

Overview

This study presents the development and efficacy of Oncostatin-M ligand-based CAR-T cells in targeting osteosarcoma. The findings indicate significant anti-tumor activity in both in vitro and in vivo models, suggesting a promising new therapeutic avenue for this challenging malignancy.

Background

Osteosarcoma is the most prevalent solid tumor in children and adolescents, with a historically low survival rate that has only recently improved. Despite advancements in treatment, including immunotherapy, there has been little progress in effective therapies for osteosarcoma over the past three decades. The introduction of CAR-T therapy targeting specific antigens presents a potential breakthrough in the treatment of this aggressive cancer.

Data Highlights

High expression of Oncostatin-M receptors was observed in osteosarcoma patient cells and cell lines. OSM-CAR-T cells demonstrated effective cytotoxicity against these cells, releasing significant amounts of IFNγ in response. In vivo studies using patient-derived xenograft models confirmed the therapeutic efficacy of OSM-CAR-T cells against osteosarcoma.

Key Findings

• OSM and its receptors are highly expressed in osteosarcoma cells, indicating a viable target for CAR-T therapy.
• OSM-CAR-T cells effectively killed osteosarcoma cells in vitro and in vivo.
• Significant release of IFNγ was observed from OSM-CAR-T cells upon interaction with osteosarcoma cells.
• OSM-CAR-T therapy shows potential for broader application in other solid tumors expressing OSM receptors.
• Development of a new pediatric patient-derived xenograft model facilitated the evaluation of OSM-CAR-T efficacy.

Clinical Implications

The findings suggest that targeting Oncostatin-M receptors with CAR-T therapy could provide a novel treatment option for osteosarcoma, particularly for patients with limited responses to current therapies. This approach may also pave the way for similar strategies in other solid tumors.

Conclusion

OSM-CAR-T therapy demonstrates significant promise in treating osteosarcoma, highlighting the need for further clinical trials to validate its efficacy and safety in patients.

References

1. Oncostatin-M ligand-based CAR-T therapy displays robust anti-tumor activity against osteosarcoma | BMC Medicine | Springer Nature, 2023
2. Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology, Fox Chase Cancer Center, 2025
3. The ASCO Post — FDA Pipeline: Breakthrough Therapy Designation in Lung Cancer, Orphan Drug Designations in Myeloma and Soft-Tissue Sarcoma
4. The ASCO Post — Cautious Optimism About Olaratumab in Soft-Tissue Sarcoma
5. the asco post — Rescue Therapy for Newly Diagnosed High-Grade Osteosarcoma
6. The ASCO Post — Advances in Sarcoma Owe Much to Children’s Oncology Group
7. FDA Pipeline: Breakthrough Therapy Designation in Lung Cancer, Orphan Drug Designations in Myeloma and Soft-Tissue Sarcoma
8. Cautious Optimism About Olaratumab in Soft-Tissue Sarcoma
9. Rescue Therapy for Newly Diagnosed High-Grade Osteosarcoma
10. Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology - Fox Chase Cancer Center
11. The clinical trial landscape of osteosarcoma: integrating trial data, immunotherapeutic trends, and biomarker insights - PMC
12. Oncostatin-M ligand-based CAR-T therapy displays robust anti-tumor activity against osteosarcoma | BMC Medicine | Springer Nature Link